SA PRO
Free Account
Sarepta Therapeutics, Inc.SRPTNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Latest News

Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags
defenseworld.net

Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags

Sarepta Therapeutics (NASDAQ: SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ELEVIDYS, highlighting what executives described as the first large, well-controlled clinical trial to measure the long-term, disease-modifying impact of a gene therapy in Duchenne muscular dystrophy (DMD) over a three-year period. Company highlights "disease-modifying" divergence from natural history Chief Executive

Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
proactiveinvestors.com

Sarepta Therapeutics shares rise on positive Duchenne gene therapy data

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3 EMBARK study evaluating its gene therapy ELEVIDYS in ambulatory patients with Duchenne muscular dystrophy. Sarepta said patients treated with ELEVIDYS demonstrated statistically significant and clinically meaningful slowing of disease progression across key functional measures compared with an untreated external control group.

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
businesswire.com

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline three-year functional results from Part 1-treated patients in EMBARK (Study SRP-9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at time of treatment and at time of las.

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
businesswire.com

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individ.

Sarepta Therapeutics: Is Elevidys A Bust?
seekingalpha.com

Sarepta Therapeutics: Is Elevidys A Bust?

Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reiterates a $500M annual revenue floor and expects normalization in ambulatory demand to support growth. SRPT fundamentals are robust, with nearly $1B in cash, no near-term debt, and a stable PMO franchise generating almost $1B in 2025 revenue.

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
businesswire.com

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Financial Update* (preliminary and unaudited) Total net product revenu.

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty
newsfilecorp.com

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) concerning whether certain officers and directors breached their fiduciary duties to the Company and its shareholders. The investigation follows the filing of a securities class action involving purchases of Sarepta securities between June 22, 2023 and June 24, 2025 (the "Class Period").

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease
businesswire.com

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT, to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. Pending approval, Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investiga.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance